Journal of Hepatology
Volume 53, Issue 2 , Pages 238-244, August 2010

Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection

  • Paul Calès

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
    • Corresponding Author InformationCorresponding author. Present address: Service d’Hépato-Gastroentérologie, CHU, 49933 Angers Cedex 09, France. Tel.: +33 2 41 35 34 10; fax: +33 2 41 35 41 19.
  • ,
  • Philippe Halfon

      Affiliations

    • Alphabio Laboratory, Marseilles, France
  • ,
  • Dominique Batisse

      Affiliations

    • Immunology Department, Hôpital Européen Georges Pompidou, Paris, France
  • ,
  • Fabrice Carrat

      Affiliations

    • INSERM, Unité de Recherche en Épidémiologie Systèmes d’Information et Modélisation (U707), Paris, F-75012, France
    • UPMC-Paris6, Faculté de Médecine Pierre et Marie Curie, UMR-S707, Paris, F-75012, France
    • Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, F-75012, France
  • ,
  • Philippe Perré

      Affiliations

    • Internal Medicine Department, CHG, La Roche/Yon, France
  • ,
  • Guillaume Penaranda

      Affiliations

    • Alphabio Laboratory, Marseilles, France
  • ,
  • Dominique Guyader

      Affiliations

    • Hepatology Department, University Hospital, Rennes, France
  • ,
  • Louis d’Alteroche

      Affiliations

    • Hepatology Department, University Hospital, Tours, France
  • ,
  • Isabelle Fouchard-Hubert

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
  • ,
  • Christian Michelet

      Affiliations

    • Infectious Diseases Department, University Hospital, Rennes, France
  • ,
  • Pascal Veillon

      Affiliations

    • Hepatology Department, University Hospital, Angers, France
    • HIFIH Laboratory, UPRES 3859, IFR 132, Angers University, PRES UNAM, France
  • ,
  • Jérôme Lambert

      Affiliations

    • INSERM, Unité de Recherche en Épidémiologie Systèmes d’Information et Modélisation (U707), Paris, F-75012, France
    • UPMC-Paris6, Faculté de Médecine Pierre et Marie Curie, UMR-S707, Paris, F-75012, France
    • Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, F-75012, France
  • ,
  • Laurence Weiss

      Affiliations

    • Immunology Department, Hôpital Européen Georges Pompidou, Paris, France
    • Hepatology Department, University Hospital, Tours, France
  • ,
  • Dominique Salmon

      Affiliations

    • Université Paris Descartes, Faculté de Médecine, Paris, France
    • Infectious Diseases, Internal Medicine Department, Hôpital Cochin, Paris, France
  • ,
  • Patrice Cacoub

      Affiliations

    • Department of Internal Medicine, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
    • Pierre and Marie Curie (Paris 6) University, CNRS UMR7087, Paris, France

Received 8 October 2009; received in revised form 13 March 2010; accepted 17 March 2010. published online 26 April 2010.

Background & Aims

We compared 5 non-specific and 2 specific blood tests for liver fibrosis in HCV/HIV co-infection.

Methods

Four hundred and sixty-seven patients were included into derivation (n=183) or validation (n=284) populations. Within these populations, the diagnostic target, significant fibrosis (Metavir F ⩾2), was found in 66% and 72% of the patients, respectively. Two new fibrosis tests, FibroMeter HICV and HICV test, were constructed in the derivation population.

Results

Unadjusted AUROCs in the derivation population were: APRI: 0.716, Fib-4: 0.722, Fibrotest: 0.778, Hepascore: 0.779, FibroMeter: 0.783, HICV test: 0.822, FibroMeter HICV: 0.828. AUROCs adjusted on classification and distribution of fibrosis stages in a reference population showed similar values in both populations. FibroMeter, FibroMeter HICV and HICV test had the highest correct classification rates in F0/1 and F3/4 (which account for high predictive values): 77–79% vs. 70–72% in the other tests (p=0.002). Reliable individual diagnosis based on predictive values ⩾90% distinguished three test categories: poorly reliable: Fib-4 (2.4% of patients), APRI (8.9%); moderately reliable: Fibrotest (25.4%), FibroMeter (26.6%), Hepascore (30.2%); acceptably reliable: HICV test (40.2%), FibroMeter HICV (45.6%) (p<10−3 between tests). FibroMeter HICV classified all patients into four reliable diagnosis intervals (⩽F1, F1±1, ⩾F1, ⩾F2) with an overall accuracy of 93% vs. 79% (p<10−3) for a binary diagnosis of significant fibrosis.

Conclusions

Tests designed for HCV infections are less effective in HIV/HCV infections. A specific test, like FibroMeter HICV, was the most interesting test for diagnostic accuracy, correct classification profile, and a reliable diagnosis. With reliable diagnosis intervals, liver biopsy can therefore be avoided in all patients.

Abbreviations: APRI, aspartate aminotransferase to platelet ratio index, AST, aspartate aminotransferase, AUROC, area under the receiver operating characteristic, CLD, chronic liver disease, HCV, hepatitis C virus, HICV, human immunodeficiency and C virus (used for HICV fibrosis test), HIV, human immunodeficiency virus, NPV, negative predictive value, PPV, positive predictive value

Keywords: Liver fibrosis, Blood test, Hepatitis C virus, Human immunodeficiency virus, Metavir staging, Diagnostic test

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(10)00271-0

doi:10.1016/j.jhep.2010.03.007

Refers to article:

  • Serum fibrosis markers: Death by validation or a leap of faith? , 11 May 2010

    Vlad Ratziu
    Journal of Hepatology August 2010 (Vol. 53, Issue 2, Pages 222-224)

Journal of Hepatology
Volume 53, Issue 2 , Pages 238-244, August 2010